Insights
Insights From Our Experts
Articles
RWEsearch 2024 | Innovating Clinical Trial Design with Real World Evidence
At the RWEsearch Annual Summit 2024, hosted by Healthark Insights, Chris Cameron, Chief Scientific Officer at EVERSANA, emphasized that advancements in Real World Evidence will accelerate with ongoing learning and use of technology and AI.
Enhancing Quality of Life in Advanced Breast Cancer: The Role of Palbociclib
Posted by
Alexandra Hall , Ngoc Nguyen , Meaghan Bartlett , Imtiaz Samjoo on September 18, 20249/18/24
Advanced breast cancer often comes with significant physical symptoms, such as pain and fatigue, as well as side effects from treatments. The diagnosis and treatment of advanced breast cancer can lead to anxiety, depression and stress.…
Preparing for Joint Clinical Assessments: How Early PICO Planning Ensures Smoother Submissions
Because the EU Health Technology Assessment (HTA) regulation will take effect in January 2025, pharmaceutical and medical device companies must prepare for a new era in health technology evaluations. The Joint Clinical Assessment (JCA), a core…
Understanding Key Reforms for High-Cost Drugs in EU4+UK Markets
Are you interested in the latest developments in high-cost drug reforms across the EU4+UK markets? Our comprehensive paper, “Understanding Key Reforms for High-Cost Drugs in EU4+UK Markets,” delves into the intricate landscape of pharmaceutical pricing and…
Tumor Types Drive Oncology Product Launch Strategies
Unlike traditional launch plans designed for blockbuster products, oncology and hematology therapy commercialization requires agility. Different tumor types and the form of therapy require distinct commercialization strategies. Patients with lung, breast, or colon cancer often undergo…
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The…
EVERSANA Experts On-Stage at Frontiers Health 2024
In anticipation of Frontiers Health 2024, EVERSANA is delighted to reveal that several of our key experts will be speaking at this top-tier global health innovation conference! Scheduled for October 17-18th in Berlin, Germany, Frontiers Health…
Canadian Market Access Success Starts With the Right Partner
The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target…
EVERSANA’s Predictive Analytics: A Capabilities Compendium
In the fast-changing world of healthcare, machine learning (ML) and real-world evidence (RWE) bring us closer to the goal of precision medicine: delivering the right treatment to the right patient by the right physicians at the…
National Institutes of Health Taps EVERSANA for Research on the Impact of Rare Disease on Patients, Healthcare System
The National Institutes of Health (NIH) has selected EVERSANA, a leading service provider to the life sciences industry, to conduct the next phase of research on the impact of rare diseases on patients and the overall…